Operating Room Systems (ORS) and Bowa Medical UK have entered a collaborative agreement to offer safe and comprehensive smoke management solutions to NHS and private healthcare providers. Under the joint venture agreement, Bowa Medical UK will work in partnership with ORS across the UK supporting the sales and marketing of the Lexion brand, consisting of three devices for the optimal surgical insufflation environment:
- the AP 50/30 intelligent CO2 conditioning insufflator delivering enhanced pneumostability, along with CO2 heating and humidification
- the InsuflowPort gas conditioning trocar
- the PneuView XE closed-circuit, active smoke eliminator
- alongside BOWA’s existing smoke management product offering – BOWA SHE SHA for open surgery and Ultravision by Alesi Surgical used in laparoscopic procedures.
Bowa is able to introduce a combined smoke management approach mitigating the risks associated with surgical smoke by offering a range of devices recommended by the Society of American Gastrointestinal and Endoscopic Surgeons (SAGES). The collaboration of these two leading medical device companies is based on cultivating their shared values, focused on delivering innovative, high quality products and providing exceptional clinical support as well as training and education.
“This collaboration with the team at Bowa Medical UK is an exciting development as we work to deliver effective CO2 conditioning and plume management solutions to our customers across the marketplace, especially at a time when the application of these technologies have never been so much to the forefront,” said Scott Hamilton, co-founder and Director at the ORS.
“The COVID-19 pandemic has taught us all the importance of mutual support and collaboration but also highlighted the raising pressures in the NHS and the risks associated with surgical smoke, we are delighted to be working alongside the ORS Team in offering our customers economically responsible solutions suited to their practices,” added Commercial Director at Bowa Medical UK, Nikki Palfrey.